Samsung Biologics, BioEleven partner on cancer immunotherapy

By The Science Advisory Board staff writers

October 19, 2020 -- Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.

BN-101A blocks programmed cell death ligand 1 (PD-L1) function and promotes anti-cancer T- cell activity. The drug has been validated in preclinical models and BioEleven plans to enter a global phase I clinical trial by 2022.

Under the agreement, Samsung Biologics will provide the full scope of its development services including cell line development, process development, nonclinicial and clinical material manufacturing, and regulatory filing support.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.